{
    "clinical_study": {
        "@rank": "45180", 
        "arm_group": [
            {
                "arm_group_label": "GLYX-13", 
                "arm_group_type": "Experimental", 
                "description": "Single IV infusion of GLYX-13, 5mg/kg,"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Single IV administration of placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The present study proposes to evaluate the potential cognitive enhancing effects of GLYX-13,\n      an NMDAR partial agonist, among a group of healthy adults and those with psychiatric illness\n      on a series of functional magnetic resonance imaging (fMRI) learning and memory tasks."
        }, 
        "brief_title": "Effects of GLYX-13 on Learning and Memory in Healthy Individuals and Those With Psychiatric Illness", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Learning and Memory in Healthy Individuals and Those With Psychiatric Illness", 
        "condition_browse": {
            "mesh_term": "Mental Disorders"
        }, 
        "detailed_description": {
            "textblock": "In a single blind randomized parallel group design, we will evaluate the whether a single\n      dose of GLYX-13 vs. placebo increases cognitive performance on tasks of learning,\n      declarative memory, and working memory, and associated task-related increases in BOLD\n      activation in hippocampus and dorsolateral prefrontal cortex, respectively.  Positive\n      findings will provide biomarker evidence for GLYX-13 effects on neural systems underlying\n      these cognitive processes."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        For all Individuals\n\n          -  Male and female subjects\n\n          -  Ages 18 - 40 years\n\n          -  General intellectual abilities falling broadly within the average range (estimated IQ\n             between 80 - 119)\n\n          -  Sufficient ability to understand study requirements and provide written informed\n             consent\n\n        For Patients\n\n        -Diagnosis of Schizophrenia or Schizoaffective Disorder\n\n        Exclusion Criteria:\n\n        For all individuals:\n\n          -  History of neurologic disorder or systemic medical condition that may interfere with\n             central nervous system function\n\n          -  History of seizures\n\n          -  History of heard injury with loss of consciousness or concussion\n\n          -  Positive screen for drugs of abuse: cocaine, marijuana, PCP, ketamine, opioid, or\n             other agent that is being abused in the opinion of the investigator\n\n          -  Females who are currently pregnant or plan to become pregnant during the study period\n\n          -  History of allergy, sensitivity, or intolerance to N-methyl-D-Aspartate receptor\n             (NMDAR) ligands including ketamine, dextromethorphan, memantine, methadone,\n             dextropropoxyphene, or ketobemidone\n\n          -  History of any ferromagnetic object in the body\n\n          -  Presence of any medical device or implant for which MRI is contraindicated including\n             cardiac pacemaker, aneurysm clip, cochlear implant, copper intrauterine device (IUD),\n             neurostimulator, or any other device deemed unsafe\n\n          -  Bullet or shrapnel in body\n\n          -  Metallic braces or permanent retainer\n\n          -  Significant claustrophobia\n\n        For Healthy Individuals\n\n          -  Personal history of any Axis I disorder according to SCID criteria\n\n          -  History of treatment with antidepressant, antipsychotic, stimulant,sedative/\n             hypnotic, mood stabilizing, or anticholinergic medications or lithium\n\n          -  History among first-degree family members of any psychotic illness or major mood\n             disorder (e.g., major depressive disorder, recurrent; bipolar I or II disorder)\n\n        For Patients\n\n          -  Treatment with Clozaril\n\n          -  Change in medication within 1 month\n\n          -  Hospitalization within 1 month"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "40 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01844726", 
            "org_study_id": "STU77430"
        }, 
        "intervention": [
            {
                "arm_group_label": "GLYX-13", 
                "description": "Single injection (5 mg/kg) of GLYX-13, an NMDAR partial agonist", 
                "intervention_name": "GLYX-13", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Single injection of placebo (saline)", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "N-Methylaspartate"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "healthy individuals", 
            "schizophrenia", 
            "schizoaffective disorder", 
            "learning", 
            "memory", 
            "cognitive enhancement", 
            "fMRI"
        ], 
        "lastchanged_date": "May 22, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Chicago", 
                    "country": "United States", 
                    "state": "Illinois", 
                    "zip": "60611"
                }, 
                "name": "Northwestern University"
            }, 
            "investigator": [
                {
                    "last_name": "James L Reilly, PhD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "John G Csernansky, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Functional Neuroimaging Effects of the N-methyl-D-aspartate Receptor (NMDAR) Partial Agonist, GLYX-13, on Learning and Memory in Healthy Individuals", 
        "overall_contact": {
            "email": "t-karpouzian@northwestern.edu", 
            "last_name": "Tatiana Karpouzian, BA", 
            "phone": "312-695-1974"
        }, 
        "overall_contact_backup": {
            "email": "marko.mihailovic@northwestern.edu", 
            "last_name": "Marko Mihailovic, MA", 
            "phone": "312-695-8173"
        }, 
        "overall_official": {
            "affiliation": "Northwestern University", 
            "last_name": "James L Reilly, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Evidence of enhanced fMRI BOLD signal change during learning, declarative memory, and working memory tasks among individuals receiving GLYX-13 administration compared to those receiving placebo.", 
            "measure": "Enhanced neural activation underlying episodic learning, declarative memory, and working memory performance", 
            "safety_issue": "No", 
            "time_frame": "within 1 hour of administration"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01844726"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Northwestern University", 
            "investigator_full_name": "James Reilly", 
            "investigator_title": "Assistant Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Evidence of persistence of enhanced learning, declarative memory, and working memory behavioral performance among individuals receiving GLYX-13 administration compared to those receiving placebo.", 
                "measure": "Persistence of enhanced learning, declarative memory, and working memory behavioral performance", 
                "safety_issue": "No", 
                "time_frame": "within 1 week of administration"
            }, 
            {
                "description": "Evidence of enhanced learning, declarative memory, and working memory performance among individuals receiving GLYX-13 administration compared to those receiving placebo.", 
                "measure": "Episodic learning, declarative memory, and working memory behavioral performance", 
                "safety_issue": "No", 
                "time_frame": "within 1 hour of administration"
            }
        ], 
        "source": "Northwestern University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Northwestern University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}